Paper Details

  1. Home
  2. Paper Details

Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.

Author: AryalSubhash, CharneyElizabeth, GruberReut, NewcornJeffrey H, SableCraig, SteinMark A, WaldmanIrwin D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts (ER MAS) were effective in reducing ADHD symptoms. Improvement in symptoms was strongly associated with increasing dose for both drugs. About 80% of patients showed reliable change on ADHD Rating Scale-IV at the highest dose level of each drug.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the dose effects of long-acting extended-release dexmethylphenidate (ER d-MPH) and ER mixed amphetamine salts (ER MAS) on attention-deficit/hyperactivity disorder (ADHD) symptom dimensions, global and specific impairments, and common adverse events associated with stimulants. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243461/

データ提供：米国国立医学図書館（NLM）

Dose Effects and Comparative Effectiveness of Extended Release Dexmethylphenidate and Mixed Amphetamine Salts

This study explores the efficacy and safety of two commonly prescribed medications for attention-deficit/hyperactivity disorder (ADHD): extended-release dexmethylphenidate (ER d-MPH) and extended-release mixed amphetamine salts (ER MAS). The researchers compared the effects of different dosages of each medication in children and adolescents with ADHD, finding that both medications effectively reduced ADHD symptoms, with improvements correlated to increasing doses.

ER d-MPH and ER MAS: Effective Treatments for ADHD

This study confirms that both ER d-MPH and ER MAS are effective treatments for ADHD. The researchers found that both medications effectively reduced ADHD symptoms and that increasing dosages were generally associated with greater improvement.

Tailoring Treatment for Individual Needs

This study emphasizes the importance of individualized treatment approaches for ADHD. While both medications were effective, some children responded better to one medication than the other. The researchers also found that different dose levels were optimal for different individuals, highlighting the need to carefully tailor treatment to individual needs.

Dr. Camel's Conclusion

This study provides valuable insights into the effectiveness and safety of ER d-MPH and ER MAS in the treatment of ADHD. The findings highlight the importance of individualized treatment approaches and suggest that both medications can be effective when properly tailored to meet the unique needs of each patient.
Date :
  1. Date Completed 2012-04-24
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22136094

DOI: Digital Object Identifier

PMC3243461

Related Literature

Article Analysis
・Side Effects of dexmethylphenidate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.